Osgood — Schlatter disease — how to improve the treatment results?

The study is aimed at improving treatment of Osgood — Schlatter disease by reducing periods of pain relief and clinical and radiological recovery, minimizing the relapses of the disease and rehabilitation period. The study involved 70 people (aged from 8 to 18 y.o., the mean age 13 y.o.) with a diagnosis of Osgood — Schlatter disease, types 1-4, based on clinical and radiological data. The patients were divided into two groups: basic and control ones, both receiving comprehensive treatment, which included lifestyle correction, physiotherapy, and therapeutic exercises for the knee joints. In addition, each patient of the basic group received one injection of platelet-rich autoplasma, and as a result, in 3 days after the injection the pain syndrome completely stopped. In the control examination one week after the injection, the edema in the upper third of the leg significantly decreased, and the range of motion in the knee joint fully restored. Three months after the injection, all adolescents returned to active lifestyle, physical activity and sports. Complications and relapses of the disease were not observed during monitoring for 12 months. The use of platelet-rich autoplasma stimulating reparative osteogenesis for the treatment of Osgood — Schlatter disease (types 1-4) results in highly effective treatment due to minimally invasive intervention, shortening the time of pain syndrome, and shortening the period of rehabilitation and return to active lifestyle.

The Antinociceptive Activities of Certain NSAIDS Combinations in Murine Orofacial Test

Pain models are mostly in rodents and between them formalin orofacial test allow discrimination among antinociception and anti-inflammation. This assay use a formalin solution injected into the upper right lip of each mouse which produces two periods of pain separated by an inactive period. The aims of the present study were to evaluate, by means of the isobolographic analysis, the antinociception and anti-inflammatory activities of the following NSAIDs: dexketoprofen, diclofenac, piroxicam and metamizole in an orofacial. The NSAIDs administered intraperitoneally produced a dose-dependent activity with the following order of potency of the rubbing behavior, in phase I: diclofenac>dexketoprofen>piroxicam>metamizole and in the phase II: metamizole>diclofenac>piroxicam>dexketoprofen. The coadministration of NSAIDs resulted in a synergistic interaction, which according to the value of the potency of the combination (II) presents the following range: dexketoprofen plus metamizole>dexketoprofen plus diclofenac>dexketoprofen plus piroxicam, in phase I and dexketoprofen plus metamizole>dexketoprofen plus piroxicam>dexketoprofen plus diclofenac, on the phase II. Data obtained in this work corroborate that NSAIDs alone or in combination inducing activities by additional mechanism of action supplementary to inhibition of COXs. This fact represent a novel approach that could be used as multimodal management of orofacial pain, since with this treatment strategies, by the reduction of doses, can help to diminish side effects of other dugs such opioids.